Parkside Financial Bank & Trust’s Cardiff Oncology CRDF Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$501	Buy	+385	New	+$611	﹤0.01%	2599

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Parkside Financial Bank & Trust's CRDF Position: Q2 2026 in Review

Parkside Financial Bank & Trust opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 385 shares worth $501. The stake represents ﹤0.01% of the portfolio and ranks #2599 among its holdings.

105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Parkside Financial Bank & Trust held 385 shares of Cardiff Oncology worth $501 as of Q2 2026.
Cardiff Oncology was a new Parkside Financial Bank & Trust position in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q2 2026, its #2599 holding.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.